The growing requirement for earmarked therapies prominently in oncology and detrimental disease handling is boosting the personalized medicine biomarkers market.
New York, USA, Dec. 17, 2024 (GLOBE NEWSWIRE) — Market Details
The global personalized medicine biomarkers market size is projected to grow from USD 21.85 billion in 2024 to USD 78.27 billion by 2034, at a CAGR of 13.6%, according to a new report by Polaris Market Research.
Market Overview
Biomarkers in personalized medicine can help in the premature identification and detection of illness prominently by earmarking molecular signatures or specified deformities that are connected to a condition. For instance, elevated levels of specific proteins in blood could indicate cancer exists in the body. They can also become handy particulars instruments for prognosis, that is forecasting how an illness is disposed to advance or run its course. This is capable of assisting doctors in evaluating how the illness will advance over time and the probability of it recurring.
Download Free Sample PDF Copy of Report:
Key Insights from Report
- The market for personalized medicine biomarkers is significantly shaped by inventions in genomics, proteomics and bioinformatics.
- The personalized medicine biomarkers market segmentation is mainly based on indication, application, and region.
- Based on application, the treatment selection segment is expected to experience the highest CAGR during the forecast period.
- By region, the report provides market insights into Asia Pacific, Europe, North America, Latin America, and the Middle East & Africa.
Personalized Medicine Biomarkers Market Scope
| Report Attributes | Details |
| Market size value in 2024 | USD 21.85 billion |
| Market size value in 2025 | USD 24.80 billion |
| Revenue Forecast in 2034 | USD 78.27 billion |
| CAGR | 13.6% from 2025 to 2034 |
| Base year | 2024 |
| Historical data | 2020-2023 |
| Forecast period | 2025-2034 |
Market’s Growth Drivers
Growing Concentration on Premature Diagnosis: Growing concentration on premature diagnosis and prohibitive healthcare pushes biomarker acquisition for personalized medicines. Additionally, pharmaceutical and biotech firms are funding massively in biomarker research to advance more productive patient treatments, contributing to the personalized medicine biomarkers market growth.
Growing Existence of Detrimental Illnesses: The growing existence of detrimental illnesses is driving the demand for the market. Growing instances of conditions, such as cardiovascular illness, diabetes, and cancer are generating an escalating requirement for personalized treatments, rendering biomarkers important for earmarked therapies. For instance, the World Health Organization (WHO) approximated roughly 20 million contemporary cancer cases worldwide in 2022.
partnership between Pharmaceutical and Diagnostic Firms: Associations between pharmaceutical and diagnostic firms are driving market growth with surgical alliances concentrated on co-advancing biomarker-established therapies and diagnostic tests. For instance, in October 2024, ADx NeuroSciences and Alamar Biosciences joined hands to convey customized blood-dependent biomarker assays to improve biopharmaceutical clinical advancements.
Request for Discount on this Report Before Purchase:
List of Personalized Medicine Biomarkers Market Key Players
- Laboratory Corporation of America Holding
- Quest Diagnostics Incorporated
- Agilent Technologies, Inc.
- Genome Medical, Inc.
- Coriell Life Sciences.
- Thermo Fisher Scientific Inc.
- NeoGenomics Laboratories
- FOUNDATION MEDICINE, INC.
- Illumina, Inc.
- Guardant Health
Geographical Analysis
North America accounted for the largest personalized medicine biomarkers market share. This is due to its progressive healthcare framework, escalated degree of funding in research and development, and robust existence of spearheading pharmaceutical and biotechnology firms.
Asia Pacific is also expected to grow at the highest CAGR during the forecast period owing to the region’s speedily augmenting healthcare framework, growing funding in biotechnology, and escalating demand for precision medicine. Governments in nations such as China, India, and Japan are growingly reinforcing enterprises targeted at enhancing healthcare systems and progressive research in biomarkers. Further, the growing existence of detrimental illnesses such as cancer and diabetes, together with a growing consciousness of customized treatments, pushes the market forward.
Inquire more about this report before purchasing:
Market Segmentation
By Indication Outlook
- Oncology
- By Type
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Others
- By Circulating Biomarkers
- Circulating Tumor Cells(CTCs)
- Circulating Cell-free DNA(cfDNA)
- Extracellular Vesicles (EVs)
- Other Circulating Biomarkers
- By Type
- Neurology
- Diabetes
- Autoimmune Diseases
- Cardiology
- Others
By Application Outlook
- Early Detection/Screening
- Diagnosis
- Treatment Selection
- Monitoring
By Regional Outlook
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
More Trending Latest Reports by Polaris Market Research:
Autonomous Emergency Braking (AEB) System Market
Automotive Catalytic Converter Market
Automotive Collision Repair Market
Automotive Transmission Market
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
- Summa Defence Oyj’s new name has been registered in the Trade register, the trading symbols have been changed, new shares have been registered in the Trade Register and the acquired treasury shares have been cancelled - June 10, 2025
- Bigbank AS Invites to Attend Webinars Introducing Public Subordinated Bond Offering - June 10, 2025
- Tarkett Participation- AVAILABILITY OF THE OTHER INFORMATION DOCUMENT RELATING TO THE LEGAL, FINANCIAL, ACCOUNTING AND OTHER CHARACTERISTICS OF TARKETT PARTICIPATION - June 10, 2025
